# EDGAR Filing Document

**Accession Number:** 0001035354
**File Stem:** 0001193125-26-214890
**Filing Date:** 2026-5
**Character Count:** 11436
**Document Hash:** be178a505ecb6597cd6c052cfcb6e501
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-214890.hdr.sgml**: 20260508

**ACCESSION NUMBER**: 0001193125-26-214890

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20220206

**FILED AS OF DATE**: 20260508

**DATE AS OF CHANGE**: 20260508

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Aggarwal Sumit
- **CENTRAL INDEX KEY:** 0001854362

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-31326
- **FILM NUMBER:** 26959378

**MAIL ADDRESS:**
- **STREET 1:** P.O. BOX 274
- **CITY:** ARLINGTON
- **STATE:** MA
- **ZIP:** 02476
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Eloxx Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001035354
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 841368850
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** P.O. BOX 274
- **CITY:** ARLINGTON
- **STATE:** MA
- **ZIP:** 02476
- **BUSINESS PHONE:** 781-577-5300

**MAIL ADDRESS:**
- **STREET 1:** P.O. BOX 274
- **CITY:** ARLINGTON
- **STATE:** MA
- **ZIP:** 02476

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Sevion Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20140930

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SENESCO TECHNOLOGIES INC
- **DATE OF NAME CHANGE:** 19991006

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NAVA LEISURE USA INC
- **DATE OF NAME CHANGE:** 19970310

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Aggarwal Sumit<br><sub>(Last) (First) (Middle)</sub><br>C/O ELOXX PHARMACEUTICALS, INC.<br>P.O. BOX 274<br><sub>(Street)</sub><br>ARLINGTON, MA 02476<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2022-02-06 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [X] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_President and CEO_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Eloxx Pharmaceuticals, Inc. [ ELOX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2025-08-14 |  | M |  | 196880 | A | $0.0001 | 396810 | D |  |
| Common Stock | 2025-09-19 |  | A |  | 1000000<sup>(1)</sup> | A | $0 | 1396810 | D |  |
| Common Stock | 2026-01-24 |  | M |  | 15000 | A | <sup>(2)</sup> | 1411810 | D |  |
| Common Stock | 2026-02-28 |  | M |  | 260946 | A | $0.15 | 1672756 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | $18.40 | 2022-02-06 |  | A |  | 42790<sup>(4)</sup> |  | <sup>(3)</sup> | 2032-02-06 | Common Stock | 42790 | $0 | 42790 | D |  |
| Stock Option (Right to Buy) | $18.40 | 2024-10-16 |  | D |  |  | 42790<sup>(4)</sup> | <sup>(3)</sup> | 2032-02-06 | Common Stock | 42790 | <sup>(5)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $0.0001 | 2024-10-16 |  | A |  | 42790 |  | <sup>(3)</sup> | 2032-02-06 | Common Stock | 42790 | <sup>(5)</sup> | 42790 | D |  |
| Stock Option (Right to Buy) | $3.36 | 2024-10-16 |  | D |  |  | 35580<sup>(4)</sup> | <sup>(6)</sup> | 2031-04-01 | Common Stock | 35580 | <sup>(7)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $0.0001 | 2024-10-16 |  | A |  | 35580 |  | <sup>(6)</sup> | 2031-04-01 | Common Stock | 35580 | <sup>(7)</sup> | 35580 | D |  |
| Stock Option (Right to Buy) | $1.41 | 2024-10-16 |  | D |  |  | 24810<sup>(4)</sup> | <sup>(6)</sup> | 2031-04-01 | Common Stock | 24810 | <sup>(8)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $0.0001 | 2024-10-16 |  | A |  | 24810 |  | <sup>(6)</sup> | 2031-04-01 | Common Stock | 24810 | <sup>(8)</sup> | 24810 | D |  |
| Stock Option (Right to Buy) | $4.27 | 2024-10-16 |  | D |  |  | 68700 | <sup>(9)</sup> | 2033-01-25 | Common Stock | 68700 | <sup>(10)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | $0.0001 | 2024-10-16 |  | A |  | 68700 |  | <sup>(9)</sup> | 2033-01-25 | Common Stock | 68700 | <sup>(10)</sup> | 68700 | D |  |
| Stock Option (Right to Buy) | $0.0001 | 2025-08-14 |  | M |  |  | 60390 | <sup>(6)</sup> | 2031-04-01 | Common Stock | 60390 | $0 | 0 | D |  |
| Stock Option (Right to Buy) | $0.0001 | 2025-08-14 |  | M |  |  | 68700 | <sup>(9)</sup> | 2033-01-25 | Common Stock | 68700 | $0 | 0 | D |  |
| Stock Option (Right to Buy) | $0.0001 | 2025-08-14 |  | M |  |  | 25000 | <sup>(11)</sup> | 2033-08-23 | Common Stock | 25000 | $0 | 0 | D |  |
| Stock Option (Right to Buy) | $0.0001 | 2025-08-14 |  | M |  |  | 42790 | <sup>(3)</sup> | 2032-02-06 | Common Stock | 42790 | $0 | 0 | D |  |
| Stock Option (Right to Buy) | $0.15 | 2025-09-19 |  | A |  | 3597090 |  | <sup>(12)</sup> | 2035-09-19 | Common Stock | 3597090 | $0 | 3597090 | D |  |
| Restricted Stock Units | <sup>(2)</sup> | 2026-01-24 |  | M |  |  | 15000 | <sup>(13)</sup> | <sup>(13)</sup> | Common Stock | 15000 | $0 | 15000 | D |  |
| Stock Option (Right to Buy) | $0.15 | 2026-02-28 |  | M |  |  | 260946 | <sup>(12)</sup> | 2035-09-19 | Common Stock | 260946 | $0 | 3336144 | D |  |

---

### Footnotes:

(1) Represents a grant of restricted stock units ("RSUs") that was fully vested upon grant.

(2) Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

(3) The stock option vested and became exercisable over the four-year period commencing February 6, 2022, with one-fourth of the shares of common stock underlying the options vesting on February 6, 2023, and the remainder vesting in twelve equal quarterly installments thereafter. The Board accelerated vesting on the unvested portion in connection with the exercise.

(4) On December 1, 2022, the Issuer effected a 1-for-40 reverse stock split. The share count has been adjusted to reflect the reverse stock split.

(5) The reporting person agreed to cancellation of an option granted to him on February 6, 2022 in exchange for a new option having a lower exercise price.

(6) The stock option vested and became exercisable over the four-year period commencing April 1, 2021, with one-fourth of the shares of common stock underlying the options vesting on April 1, 2022, and the remainder vesting in twelve equal quarterly installments thereafter.

(7) The reporting person agreed to cancellation of an option granted to him on April 1, 2021 in exchange for a new option having a lower exercise price.

(8) The reporting person agreed to cancellation of an option granted to him on May 18, 2021 in exchange for a new option having a lower exercise price.

(9) The option vested and became exercisable as to 25% of the underlying shares on the first anniversary of January 25, 2023, and the remaining 75% of the underlying shares vested in 12 equal quarterly installments thereafter.  The Board accelerated vesting on the unvested portion in connection with the exercise.

(10) The reporting person agreed to cancellation of an option granted to him on January 25, 2023 in exchange for a new option having a lower exercise price.

(11) The option was granted on August 23, 2023 and was scheduled to vest subject to certain performance criteria, which the Board waived in connection with the exercise.

(12) The option vests as follows: (i) as to 1,736,275 shares, vested 1/36 on October 31, 2025, with the remaining options vesting thereafter in equal consecutive monthly increments over 35 months; (ii) as to 612,245 shares, vested 1/36 on January 31, 2026, with the remaining options vesting thereafter in equal consecutive monthly increments over 35 months; and (iii) as to 1,248,570 shares, vested 1/36 on March 31, 2026, with the remaining options vesting thereafter in equal consecutive monthly increments over 35 months, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.

(13) The RSUs vested as to 50% on the first anniversary of January 24, 2024 and the remaining amount vested in two equal annual installments thereafter.

**Signature:** /s/ Sumit Aggarwal  
**Date:** 2026-05-08

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**